Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Andrew Gomperts | M | - |
Hillhurst Biopharmaceuticals, Inc.
 Hillhurst Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Hillhurst Biopharmaceuticals, Inc. is a private company that specializes in developing a gas in liquid advanced stability system called Hillhurst's proprietary GLASSTM platform. The company is based in San Diego, CA. This platform enables novel uses of therapeutic gases that were previously limited by inhaled delivery. The company has developed a unique pipeline of novel liquid therapeutic candidates intended to treat patients with sickle cell disease, Parkinson's disease, and acute pain. The company was founded by Edward Gomperts. The CEO is Andrew Gomperts. | - |
| Douglas Stockdale | M | - |
Hillhurst Biopharmaceuticals, Inc.
Hillhurst Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Hillhurst Biopharmaceuticals, Inc. is a private company that specializes in developing a gas in liquid advanced stability system called Hillhurst's proprietary GLASSTM platform. The company is based in San Diego, CA. This platform enables novel uses of therapeutic gases that were previously limited by inhaled delivery. The company has developed a unique pipeline of novel liquid therapeutic candidates intended to treat patients with sickle cell disease, Parkinson's disease, and acute pain. The company was founded by Edward Gomperts. The CEO is Andrew Gomperts. | - |
| Jeff Friedman | M | - |
Hillhurst Biopharmaceuticals, Inc.
Hillhurst Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Hillhurst Biopharmaceuticals, Inc. is a private company that specializes in developing a gas in liquid advanced stability system called Hillhurst's proprietary GLASSTM platform. The company is based in San Diego, CA. This platform enables novel uses of therapeutic gases that were previously limited by inhaled delivery. The company has developed a unique pipeline of novel liquid therapeutic candidates intended to treat patients with sickle cell disease, Parkinson's disease, and acute pain. The company was founded by Edward Gomperts. The CEO is Andrew Gomperts. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 3 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Edward Gomperts
- Persönliches Netzwerk
